Our results also indicate that the CXCL12-induced gemcitabine resistance in pancreatic cancer cells might, in part, also be due to the activation of NF-κB and induction of downstream survival proteins (Bcl-2, Bcl-xL, survivin, and so on). Here, CXCL12 is linked to pancreatic neoplasm.